TMC114 — Competitive Intelligence Brief

TMC114 (TMC114) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: protease inhibitor. Area: Infectious Diseases.

phase 3 protease inhibitor HIV-1 protease Infectious Diseases Small molecule

Target snapshot

TMC114 (TMC114) — Tibotec Pharmaceuticals, Ireland. TMC114 is a protease inhibitor used to treat HIV-1 infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TMC114 TARGET	TMC114	Tibotec Pharmaceuticals, Ireland	phase 3	protease inhibitor	HIV-1 protease
Riv	riv	Pfizer	marketed	Protease Inhibitors	HIV-1 protease
Triple therapy with ritonavir	Triple therapy with ritonavir	Sociedad Andaluza de Enfermedades Infecciosas	marketed	HIV protease inhibitor	HIV-1 protease
abacavir/lamivudine + darunavir/ritonavir	abacavir/lamivudine + darunavir/ritonavir	University of Modena and Reggio Emilia	phase 3	NRTI + PI	HIV-1 reverse transcriptase, HIV-1 protease
Tipranavir/Ritonavir	Tipranavir/Ritonavir	Johns Hopkins University	phase 3	Protease inhibitor	HIV-1 protease
TMC435	TMC435	Tibotec Pharmaceuticals, Ireland	phase 3	protease inhibitor	HIV-1 protease
continue the PI/r-containing HAART.	continue the PI/r-containing HAART.	ASST Fatebenefratelli Sacco	phase 3	Protease inhibitor	HIV-1 protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (protease inhibitor class)

1. Tibotec Pharmaceuticals, Ireland · 3 drugs in this class
2. AbbVie · 1 drug in this class
3. AbbVie (prior sponsor, Abbott) · 1 drug in this class
4. R-Pharm · 1 drug in this class
5. Tanabe Pharma Corporation · 1 drug in this class